We develop diverse therapeutics that can be applied in the treatment of
various indications related to inflamed and leaky blood vessels.

We have targeted ophthalmic diseases as our first indication and completed a joint research and technology transfer agreement with a global biotech company specializing in ophthalmic diseases, proving its unique technological strength and value.
With the territory of ophthalmic diseases as its strategic foothold and new therapeutic candidates already secured, we have established a solid roadmap and portfolio that can be expanded into therapies for systemic diseases including various vasculitis, cancer and the kidney diseases.